Trial Profile
A Study Investigating the Clinical and Metabolic Benefits of Dapagliflozin plus Saxagliptin Combination in Type-II Diabetes Mellitus (T2D) Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Dapagliflozin/saxagliptin (Primary) ; Dapagliflozin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- 12 Jul 2020 Results published in the Diabetes Care.
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 22 Jul 2018 New trial record